Generex Biotechnology Initiates Peptide Manufacturing for Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
May 04, 2020 08:30 ET
|
Generex Biotechnology Corporation
Submitted proposal to BARDA for start-to-finish funding to develop an approved, commercial Ii-Key peptide vaccine against the SARS-CoV-2 coronavirusSARS-CoV-2 epitope identification and selection...
Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial
April 28, 2020 09:24 ET
|
Generex Biotechnology Corporation
Prospective, randomized, single‑blinded, multi‑center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence Conclusion: AE37 Ii-Key peptide...
Generex Biotechnology Publishes Response to Congressional Letter Calling for COVID-19 Challenge Studies and Alternative Solution to Accelerate Vaccine Development
April 27, 2020 08:30 ET
|
Generex Biotechnology Corporation
Generex strategy offers ethical and safe solution to rapid vaccine development with Ii-Key-SARS-CoV-2 peptide vaccineSARS-CoV-2 mechanism of infection still largely unknownCOVID-19 disease progression...
Generex Biotechnology Provides Update on the Development of an Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
April 14, 2020 09:00 ET
|
Generex Biotechnology Corporation
MIRAMAR, Fla., April 14, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company is...
Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic
April 06, 2020 09:09 ET
|
Generex Biotechnology Corporation
MIRAMAR, Fla., April 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) President & CEO Joseph Moscato...
Generex Biotechnology Subsidiary Olaregen Therapeutics’ Wound Conforming Matrix, Excellagen®, Awarded Strategic Acquisition Centers (SAC) Biologic Blanket Purchase Agreement (BPA) Contract
March 30, 2020 10:00 ET
|
Generex Biotechnology Corporation
The BPA contract facilitates the sales and distribution of Excellagen across the VA system’s 165 hospitalsExcellagen wound conforming matrix is used to manage wounds including Diabetic Foot Ulcers,...
Generex Participating on Expert Panel for Fierce Pharma & Fierce Healthcare Corona Virus Virtual Series
March 30, 2020 08:30 ET
|
Generex Biotechnology Corporation
MIRAMAR, Fla., March 30, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) announced that today Dr. Eric von...
Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2 Coronavirus Pandemic
March 19, 2020 09:00 ET
|
Generex Biotechnology Corporation
Generex’s Ii-Key peptide vaccines for infectious disease and cancer have been studied in human clinical trials involving over 300 subjects in Phase I and Phase II clinical trialsSee publications at...
Generex Subsidiary NuGenerex Immuno-Oncology (Formerly Antigen Express) Files Form 10 Registration Statement with the Securities and Exchange Commission
March 12, 2020 13:13 ET
|
Generex Biotechnology Corporation
NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseasesNGIO advancing...
Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media
March 11, 2020 14:40 ET
|
Generex Biotechnology Corporation
MIRAMAR, Fla., March 11, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT), and its subsidiary, NuGenerex Immune-Oncology (NGIO), have been featured in several news outlets and...